MDRNA, Inc. (MRNA) Signs Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology
MDRNA, Inc. announced today that it has entered into a licensing agreement with Novartis for MDRNA's liposomal technology platform for siRNA delivery. According to the press release, MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. The companies also entered into a separate agreement that provides Novartis with an exclusive period to negotiate a research and development collaboration and broader licensing rights related to MDRNA's RNAi drug delivery platform. J. Michael French, President and Chief Executive Officer of MDRNA, stated, "We are pleased to enter into this agreement with Novartis, a global leader in the field of…